# A Phase 1 Study of [225Ac]-FPI-1434 Injection

> **NCT03746431** · PHASE1 · TERMINATED · sponsor: **Fusion Pharmaceuticals Inc.** · enrollment: 78 (actual)

## Conditions studied

- Advanced Solid Tumours
- Endometrial Cancer
- Cervical Cancer
- Ovarian Cancer
- Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- HER2-negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Adrenocortical Carcinoma
- Uveal Melanoma

## Interventions

- **DRUG:** [111In]-FPI-1547 Injection
- **DRUG:** [225Ac]-FPI-1434 Injection multi-dose
- **BIOLOGICAL:** FPI-1175 Infusion
- **DRUG:** [225Ac]-FPI-1434 Injection single-dose

## Key facts

- **NCT ID:** NCT03746431
- **Lead sponsor:** Fusion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-17
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746431, "A Phase 1 Study of [225Ac]-FPI-1434 Injection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03746431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*